<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20250123072024&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20250123072024&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 23 Jan 2025 12:20:25 +0000</lastbuilddate>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>NEDD4-Mediated GSNOR Degradation Aggravates Cardiac Hypertrophy and Dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39846173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings showed that upregulated NEDD4 leads to GSNOR ubiquitination and subsequent degradation, thereby facilitating the progression of cardiac hypertrophy. NEDD4 inhibitors may serve as a potential therapeutic strategy for the treatment of cardiac hypertrophy and heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 23. doi: 10.1161/CIRCRESAHA.124.324872. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The decrease in S-nitrosoglutathione reductase (GSNOR) leads to an elevation of S-nitrosylation, thereby exacerbating the progression of cardiomyopathy in response to hemodynamic stress. However, the mechanisms under GSNOR decrease remain unclear. Here, we identify NEDD4 (neuronal precursor cell expressed developmentally downregulated 4) as a novel molecule that plays a crucial role in the pathogenesis of pressure overload-induced cardiac hypertrophy, by modulating GSNOR levels, thereby demonstrating significant therapeutic potential.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Protein synthesis and degradation inhibitors were used to verify the reasons for the decrease in GSNOR. Mass spectrometry and database filtering were used to uncover NEDD4, the E3 Ub (ubiquitin) ligase, involved in GSNOR decrease. NEDD4 cardiomyocyte-specific deficiency mice were used to evaluate the role of NEDD4 and NEDD4-induced ubiquitination of GSNOR in cardiac hypertrophy in vivo. Both IBM, a highly specific NEDD4 inhibitor, and indole-3-carbinol, a NEDD4 inhibitor currently undergoing phase 2 clinical trial, were used to effectively suppress the NEDD4/GSNOR axis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: GSNOR protein levels were reduced, while mRNA levels remained unchanged in myocardium samples from hypertrophic patients and transverse aortic constriction-induced mice, indicating GSNOR is regulated by ubiquitination. NEDD4, an E3 Ub ligase, was associated with GSNOR ubiquitination, which exhibited significantly higher expression levels in hypertrophic myocardial samples. Moreover, either the NEDD4 enzyme-dead mutant or GSNOR nonubiquitylated mutant decreased GSNOR ubiquitination and inhibited cardiac hypertrophic growth. Cardiomyocyte-specific NEDD4 deficiency inhibited cardiac hypertrophy in vitro and in vivo. NEDD4 inhibitor IBM effectively suppressed GSNOR ubiquitination and cardiac hypertrophy. Clinically, indole-3-carbinol, a NEDD4 inhibitor in phase II clinical trials used as an antitumor drug, demonstrated comparable efficacy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings showed that upregulated NEDD4 leads to GSNOR ubiquitination and subsequent degradation, thereby facilitating the progression of cardiac hypertrophy. NEDD4 inhibitors may serve as a potential therapeutic strategy for the treatment of cardiac hypertrophy and heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39846173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39846173</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324872>10.1161/CIRCRESAHA.124.324872</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39846173</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Xin Tang</dc:creator>
<dc:creator>Xiameng Liu</dc:creator>
<dc:creator>Xinqi Sha</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:creator>Yan Zu</dc:creator>
<dc:creator>Qiyao Fan</dc:creator>
<dc:creator>Lulu Hu</dc:creator>
<dc:creator>Shixiu Sun</dc:creator>
<dc:creator>Zhiren Zhang</dc:creator>
<dc:creator>Feng Chen</dc:creator>
<dc:creator>ChengHui Yan</dc:creator>
<dc:creator>Xin Chen</dc:creator>
<dc:creator>Yueyue Xu</dc:creator>
<dc:creator>Wen Chen</dc:creator>
<dc:creator>Yongfeng Shao</dc:creator>
<dc:creator>Jiaxi Gu</dc:creator>
<dc:creator>Jun Pu</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:creator>Yaling Han</dc:creator>
<dc:creator>Liping Xie</dc:creator>
<dc:creator>Yi Han</dc:creator>
<dc:creator>Yong Ji</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>NEDD4-Mediated GSNOR Degradation Aggravates Cardiac Hypertrophy and Dysfunction</dc:title>
<dc:identifier>pmid:39846173</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324872</dc:identifier>
</item>
<item>
<title>Placental Hypoxia-Induced Ferroptosis Drives Vascular Damage in Preeclampsia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39846172/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In pregnancy, iron and oxygen work synergistically to conserve an operative antioxidant system to maintain iron homeostasis and protect the placenta from ferroptotic death. Hindrance to this system due to hypoxia results in heightened ferroptosis rates and sEV-mediated extrusion of harmful lipid peroxides from trophoblast cells into the circulation thereby contributing to maternal endothelial dysfunction characterizing preeclampsia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 23. doi: 10.1161/CIRCRESAHA.124.325119. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Iron is an essential micronutrient for cell survival and growth; however, excess of this metal drives ferroptosis. Although maternal iron imbalance and placental hypoxia are independent contributors to the pathogenesis of preeclampsia, a hypertensive disorder of pregnancy, the mechanisms by which their interaction impinge on maternal and placental health remain elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used placentae from normotensive and preeclampsia pregnancy cohorts, human H9 embryonic stem cells differentiated into cytotrophoblast-like cells, and placenta-specific <i>Phd2</i><sup><i>-/-</i></sup> preeclamptic mice. Lipid peroxidation and iron cargo of placenta-derived small extracellular vesicles (sEVs) isolated from the maternal circulation of control and preeclampsia individuals were examined by mass spectrometry, flow cytometry, and colorimetry. Human microvascular endothelial cells' angiogenic capacity and function were examined after exposure to control and pathological sEVs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Placentae from preeclampsia pregnancies contain increased ferrous iron and lipid peroxidation byproduct, malondialdehyde. Antioxidant capacity is significantly lower in preeclampsia placentae, with decreased glutathione content, and GPx4 (glutathione peroxidase 4) expression and activity. Hypoxia triggers the occurrence of ferroptosis in human trophoblast cells and mouse <i>Phd2</i><sup><i>-</i></sup><sup><i>/-</i></sup>placentae. Disrupted placental iron homeostasis in preeclampsia is accompanied by improper extrusion of iron through sEVs mediated by the pentaspan protein prominin-2. Heightened lipid peroxidation content was found in villous explants and maternal circulating sEVs of preeclampsia individuals. Exposure of human microvascular endothelial cells to preeclampsia-derived placental sEVs results in endothelial activation and impaired angiogenesis, which is rescued by treatment with hinokitiol, a compound known to restore tissue iron balance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In pregnancy, iron and oxygen work synergistically to conserve an operative antioxidant system to maintain iron homeostasis and protect the placenta from ferroptotic death. Hindrance to this system due to hypoxia results in heightened ferroptosis rates and sEV-mediated extrusion of harmful lipid peroxides from trophoblast cells into the circulation thereby contributing to maternal endothelial dysfunction characterizing preeclampsia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39846172/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39846172</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325119>10.1161/CIRCRESAHA.124.325119</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39846172</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Chanho Park</dc:creator>
<dc:creator>Sruthi Alahari</dc:creator>
<dc:creator>Jonathan W Ausman</dc:creator>
<dc:creator>Ruizhe Liu</dc:creator>
<dc:creator>Frederik Nguyen</dc:creator>
<dc:creator>Julien Sallais</dc:creator>
<dc:creator>Martin Post</dc:creator>
<dc:creator>Isabella Caniggia</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Placental Hypoxia-Induced Ferroptosis Drives Vascular Damage in Preeclampsia</dc:title>
<dc:identifier>pmid:39846172</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325119</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2024: the top 10 papers in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39844351/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 23:ehaf017. doi: 10.1093/eurheartj/ehaf017. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39844351/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39844351</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf017>10.1093/eurheartj/ehaf017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39844351</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2024: the top 10 papers in heart failure</dc:title>
<dc:identifier>pmid:39844351</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf017</dc:identifier>
</item>
<item>
<title>Reply: Where the Definition of Fragility Came From and Where It Will Go</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e45-e46. doi: 10.1016/j.jacc.2024.10.120.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843038</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.120>10.1016/j.jacc.2024.10.120</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843038</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Mario Enrico Canonico</dc:creator>
<dc:creator>Rupert Bauersachs</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Where the Definition of Fragility Came From and Where It Will Go</dc:title>
<dc:identifier>pmid:39843038</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.120</dc:identifier>
</item>
<item>
<title>Where the Definition of Fragility Came From and Where It Will Go?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843037/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e43. doi: 10.1016/j.jacc.2024.09.1246.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843037/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843037</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1246>10.1016/j.jacc.2024.09.1246</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843037</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ruiting Jia</dc:creator>
<dc:creator>Yan Zhao</dc:creator>
<dc:creator>Aisong Zhu</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Where the Definition of Fragility Came From and Where It Will Go?</dc:title>
<dc:identifier>pmid:39843037</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1246</dc:identifier>
</item>
<item>
<title>Reply: Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843036/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e41. doi: 10.1016/j.jacc.2024.10.118.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843036/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843036</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.118>10.1016/j.jacc.2024.10.118</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843036</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Victoria L Bartlett</dc:creator>
<dc:creator>Michael Liu</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value</dc:title>
<dc:identifier>pmid:39843036</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.118</dc:identifier>
</item>
<item>
<title>Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e39-e40. doi: 10.1016/j.jacc.2024.08.089.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843035</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.089>10.1016/j.jacc.2024.08.089</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843035</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kartik Giri</dc:creator>
<dc:creator>Aman Kakkar</dc:creator>
<dc:creator>Daniel Tarditi</dc:creator>
<dc:creator>Arthur C Lee</dc:creator>
<dc:creator>Maulik Shah</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value</dc:title>
<dc:identifier>pmid:39843035</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.089</dc:identifier>
</item>
<item>
<title>Reply: Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843034/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e37. doi: 10.1016/j.jacc.2024.10.119.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843034/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843034</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.119>10.1016/j.jacc.2024.10.119</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843034</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Karl-Philipp Rommel</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study</dc:title>
<dc:identifier>pmid:39843034</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.119</dc:identifier>
</item>
<item>
<title>Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843033/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e35. doi: 10.1016/j.jacc.2024.08.090.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843033/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843033</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.090>10.1016/j.jacc.2024.08.090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843033</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Dawei Lin</dc:creator>
<dc:creator>Xiaochun Zhang</dc:creator>
<dc:creator>Wenzhi Pan</dc:creator>
<dc:creator>Daxin Zhou</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study</dc:title>
<dc:identifier>pmid:39843033</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.090</dc:identifier>
</item>
<item>
<title>Amara Yad Image: The Tricuspid Valve</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843032/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):295-296. doi: 10.1016/j.jacc.2024.12.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843032/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843032</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.026>10.1016/j.jacc.2024.12.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843032</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Amara Yad Image: The Tricuspid Valve</dc:title>
<dc:identifier>pmid:39843032</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.026</dc:identifier>
</item>
<item>
<title>The Amara Yad Project: A New Resource for Cardiac Anatomy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843031/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):292-294. doi: 10.1016/j.jacc.2024.12.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843031/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843031</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.007>10.1016/j.jacc.2024.12.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843031</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Amara Yad Project: A New Resource for Cardiac Anatomy</dc:title>
<dc:identifier>pmid:39843031</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.007</dc:identifier>
</item>
<item>
<title>Symptomatic Improvement "Only" in Unblinded Trials: The Plot Thickens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843030/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):247-249. doi: 10.1016/j.jacc.2024.11.045.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843030/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843030</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.045>10.1016/j.jacc.2024.11.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843030</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexander M Levy</dc:creator>
<dc:creator>Jarmanjeet Singh</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Symptomatic Improvement "Only" in Unblinded Trials: The Plot Thickens</dc:title>
<dc:identifier>pmid:39843030</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.045</dc:identifier>
</item>
<item>
<title>Tricuspid Valve Interventions: A New Era in Cardiovascular Innovation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843029/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):203-205. doi: 10.1016/j.jacc.2024.12.006.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843029/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39843029</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.006>10.1016/j.jacc.2024.12.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843029</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tricuspid Valve Interventions: A New Era in Cardiovascular Innovation</dc:title>
<dc:identifier>pmid:39843029</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.006</dc:identifier>
</item>
<item>
<title>Immunometabolic switch in hypertension: how dendritic cell mineralocorticoid receptors drive Th17 polarization and blood pressure control</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39842875/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 22:ehae863. doi: 10.1093/eurheartj/ehae863. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39842875/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39842875</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae863>10.1093/eurheartj/ehae863</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39842875</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Tomasz P Mikolajczyk</dc:creator>
<dc:creator>Tomasz Śliwa</dc:creator>
<dc:creator>Tomasz J Guzik</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Immunometabolic switch in hypertension: how dendritic cell mineralocorticoid receptors drive Th17 polarization and blood pressure control</dc:title>
<dc:identifier>pmid:39842875</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae863</dc:identifier>
</item>
<item>
<title>Non-neuronal ventricular cardiomyocyte-located nicotinergic acetylcholine receptors cause remodelling and arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39842853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 22:ehae845. doi: 10.1093/eurheartj/ehae845. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39842853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39842853</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae845>10.1093/eurheartj/ehae845</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39842853</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Sami F Noujaim</dc:creator>
<dc:creator>Dobromir Dobrev</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-neuronal ventricular cardiomyocyte-located nicotinergic acetylcholine receptors cause remodelling and arrhythmias</dc:title>
<dc:identifier>pmid:39842853</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae845</dc:identifier>
</item>
<item>
<title>KDM6B-dependent epigenetic programming of uterine fibroblasts in early pregnancy regulates parturition timing in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39842437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>Current efforts investigating parturition timing mechanisms have focused on the proximal triggers of labor onset generated in late pregnancy. By studying the delayed parturition phenotype of mice with uterine fibroblast deficiencies in the histone H3K27me3 demethylase KDM6B, we provide evidence that parturition timing is regulated by events that take place in early pregnancy. Immediately after copulation, uterine fibroblasts engage in a locus-specific epigenetic program that abruptly adjusts...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 13:S0092-8674(24)01432-6. doi: 10.1016/j.cell.2024.12.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Current efforts investigating parturition timing mechanisms have focused on the proximal triggers of labor onset generated in late pregnancy. By studying the delayed parturition phenotype of mice with uterine fibroblast deficiencies in the histone H3K27me3 demethylase KDM6B, we provide evidence that parturition timing is regulated by events that take place in early pregnancy. Immediately after copulation, uterine fibroblasts engage in a locus-specific epigenetic program that abruptly adjusts H3K27me3 levels across their genome. In the absence of KDM6B, many of the adjusted loci over-accumulate H3K27me3. This over-accumulation leads to nearby genes being misexpressed in mid-to-late gestation, a delayed effect partly attributable to a second locus-specific but KDM6B-independent process initiated within uterine fibroblasts soon after implantation. This second process employs progressive H3K27me3 loss to temporally structure post-midgestational patterns of gene induction. Further dissection of the ways uterine programming controls parturition timing may have relevance to human pregnancy complications such as preterm labor.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39842437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39842437</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.019>10.1016/j.cell.2024.12.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39842437</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Tara I McIntyre</dc:creator>
<dc:creator>Omar Valdez</dc:creator>
<dc:creator>Nathan P Kochhar</dc:creator>
<dc:creator>Brittany Davidson</dc:creator>
<dc:creator>Bushra Samad</dc:creator>
<dc:creator>Longhui Qiu</dc:creator>
<dc:creator>Kenneth Hu</dc:creator>
<dc:creator>Alexis J Combes</dc:creator>
<dc:creator>Adrian Erlebacher</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>KDM6B-dependent epigenetic programming of uterine fibroblasts in early pregnancy regulates parturition timing in mice</dc:title>
<dc:identifier>pmid:39842437</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.019</dc:identifier>
</item>
<item>
<title>A natural variant of COOL1 gene enhances cold tolerance for high-latitude adaptation in maize</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39842436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>Low temperature severely limits the growth, yield, and geographical distribution of maize (Zea mays L.). How maize adapts to cold climates remains largely unclear. Here, we identify a basic helix-loop-helix (bHLH) transcription factor, COLD-RESPONSIVE OPERATION LOCUS 1 (COOL1), as a crucial regulator of maize cold tolerance through genome-wide association studies. Natural variations in the COOL1 promoter affect the binding affinity of ELONGATED HYPOCOTYL5 (HY5), a transcriptional factor...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 13:S0092-8674(24)01431-4. doi: 10.1016/j.cell.2024.12.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Low temperature severely limits the growth, yield, and geographical distribution of maize (Zea mays L.). How maize adapts to cold climates remains largely unclear. Here, we identify a basic helix-loop-helix (bHLH) transcription factor, COLD-RESPONSIVE OPERATION LOCUS 1 (COOL1), as a crucial regulator of maize cold tolerance through genome-wide association studies. Natural variations in the COOL1 promoter affect the binding affinity of ELONGATED HYPOCOTYL5 (HY5), a transcriptional factor repressing COOL1 transcription. COOL1, in turn, negatively regulates downstream cold-responsive genes, thereby modulating cold tolerance. Moreover, calcium-dependent protein kinase CPK17 translocates to the nucleus and stabilizes COOL1 in response to cold stress. Intriguingly, the cold-tolerant allele of COOL1 is predominantly distributed in northern high latitudes with cold climates. This study defines a previously unknown pathway by which the COOL1-centered module regulates cold tolerance for high latitudinal adaptation in maize.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39842436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39842436</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.018>10.1016/j.cell.2024.12.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39842436</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Rong Zeng</dc:creator>
<dc:creator>Yiting Shi</dc:creator>
<dc:creator>Li Guo</dc:creator>
<dc:creator>Diyi Fu</dc:creator>
<dc:creator>Minze Li</dc:creator>
<dc:creator>Xiaoyan Zhang</dc:creator>
<dc:creator>Zhuoyang Li</dc:creator>
<dc:creator>Junhong Zhuang</dc:creator>
<dc:creator>Xiaohong Yang</dc:creator>
<dc:creator>Jianru Zuo</dc:creator>
<dc:creator>Zhizhong Gong</dc:creator>
<dc:creator>Feng Tian</dc:creator>
<dc:creator>Shuhua Yang</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A natural variant of COOL1 gene enhances cold tolerance for high-latitude adaptation in maize</dc:title>
<dc:identifier>pmid:39842436</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.018</dc:identifier>
</item>
<item>
<title>Supine Blood Pressure and Risk of Cardiovascular Disease and Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39841470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Supine hypertension regardless of seated hypertension had a higher HR for CVD risk than seated hypertension alone. Future research should evaluate supine hypertension in the setting of nocturnal hypertension and as an independent target of blood pressure treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 22. doi: 10.1001/jamacardio.2024.5213. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Nocturnal hypertension while asleep is associated with substantial increases in risk of cardiovascular disease (CVD) and death. Whether hypertension while supine is a risk factor associated with CVD independent of seated hypertension remains unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the association between supine hypertension and CVD outcomes and by hypertension treatment status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study used data from the Atherosclerosis Risk in Communities (ARIC) study, which was established in 1987 to examine cardiovascular risk factors among middle-aged adults from 4 communities in the US. Supine and seated blood pressure were measured in more than 13 000 middle-aged adults with longitudinal surveillance for CVD over 27 years. Participants with a history of coronary heart disease (CHD), heart failure, or stroke were excluded. Data were analyzed from May 2023 through December 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Supine hypertension (supine systolic blood pressure ≥130 or diastolic blood pressure ≥80 mm Hg) with and without seated hypertension (seated systolic blood pressure ≥130 or diastolic blood pressure ≥80 mm Hg).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cox proportional hazard models with adjustment for CVD risk factors were performed to investigate the association of supine hypertension with and without seated hypertension with incident CHD, heart failure, stroke, fatal CHD, and all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 11 369 participants without known CVD (6332 female [55.7%] and 5037 male [44.3%]; 2858 Black [25.1%] and 8511 White [74.9%]; mean [SD] age 53.9 [5.7] years]), 16.4% (95% CI, 15.5%-17.2%) of those without seated hypertension had supine hypertension and 73.5% (95% CI, 72.2%-74.8%) of those with seated hypertension had supine hypertension. Supine hypertension was associated with incident CHD (hazard ratio [HR], 1.60; 95% CI, 1.45-1.76), heart failure (HR, 1.83; 95% CI, 1.68-2.01), stroke (HR, 1.86; 95% CI, 1.63-2.13), fatal CHD (HR, 2.18; 95% CI, 1.84-2.59), and all-cause mortality (HR, 1.43; 95% CI, 1.35-1.52) during a median (25th, 75th percentile) follow-up of 25.7 (15.4, 30.4) years, 26.9 (17.6, 30.5) years, 27.6 (18.5, 30.6 years), 28.3 (20.5, 30.7) years, and 28.3 (20.5 years, 30.7) years, respectively. There were no meaningful differences by seated hypertension status. Results were similar by hypertension medication use. Participants with supine hypertension alone had risk associations similar to those of participants with hypertension in both positions and significantly greater than those of participants with seated hypertension alone with the exception of fatal CHD; seated vs supine HRs were 0.72 (95% CI, 0.61-0.85) for CHD, 0.72 (95% CI, 0.60-0.85) for heart failure, 0.66 (95% CI, 0.51-0.86) for stroke, and 0.83 (95% CI, 0.74-0.92) for all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Supine hypertension regardless of seated hypertension had a higher HR for CVD risk than seated hypertension alone. Future research should evaluate supine hypertension in the setting of nocturnal hypertension and as an independent target of blood pressure treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39841470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39841470</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5213>10.1001/jamacardio.2024.5213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39841470</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Duc M Giao</dc:creator>
<dc:creator>Hannah Col</dc:creator>
<dc:creator>Fredrick Larbi Kwapong</dc:creator>
<dc:creator>Ruth-Alma Turkson-Ocran</dc:creator>
<dc:creator>Long H Ngo</dc:creator>
<dc:creator>Jennifer L Cluett</dc:creator>
<dc:creator>Lynne Wagenknecht</dc:creator>
<dc:creator>B Gwen Windham</dc:creator>
<dc:creator>Elizabeth Selvin</dc:creator>
<dc:creator>Pamela L Lutsey</dc:creator>
<dc:creator>Stephen P Juraschek</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Supine Blood Pressure and Risk of Cardiovascular Disease and Mortality</dc:title>
<dc:identifier>pmid:39841470</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5213</dc:identifier>
</item>
<item>
<title>Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39841451/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This study shows that asymptomatic ATTR cardiac amyloid infiltration encompasses a wide spectrum of disease severity, with patients with grade 2 or 3 cardiac uptake experiencing an increased rate of CV events and CV mortality and patients with grade 1 uptake experiencing a lower CV event rate and predominantly non-CV mortality. These findings support the use of disease-modifying treatments in asymptomatic patients with grade 2 or 3 uptake and highlight the need of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 22. doi: 10.1001/jamacardio.2024.5221. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid infiltration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To characterize the clinical phenotype and natural history of asymptomatic patients with ATTR cardiac amyloid infiltration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed data of all patients at 12 international centers for amyloidosis from January 1, 2008, through December 31, 2023. Inclusion criteria were asymptomatic ATTR cardiac amyloid infiltration, defined as an absence of HF history, HF signs and symptoms, diuretic therapy, and plasma cell dyscrasia with evidence of myocardial uptake on bone scintigraphy. If plasma cell dyscrasia was present, histologic confirmation of ATTR amyloid was required.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Asymptomatic ATTR cardiac amyloid infiltration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcomes were all-cause and cardiovascular (CV) mortality. The secondary outcomes were unplanned HF hospitalization, unplanned CV-related hospitalization, and a composite outcome of CV mortality and HF hospitalization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study comprised 485 patients with asymptomatic ATTR cardiac amyloid infiltration (mean [SD] age, 74.9 [9.9] years, 85.8% male, 112 [23.1%] with hereditary ATTR amyloidosis), with 369 (76.1%) having grade 2 or 3 and 116 (23.9%) having grade 1 cardiac uptake at baseline. Patients with grade 2 or 3 uptake exhibited significantly more cardiac functional and structural abnormalities vs patients with grade 1 uptake. At 3 years, compared with grade 1 uptake, patients with grade 2 or 3 uptake had greater development of HF (54.3% [95% CI, 47.7%-61.3%] vs 23.1% [95% CI, 14.8%-35.1%]), greater outpatient diuretic initiation and N-terminal pro-B-type natriuretic peptide progression (35.0% [95% CI, 28.0%-43.2%] vs 12.4% [95% CI, 6.3%-23.7%]), and greater HF hospitalization (8.7% [95% CI, 5.9%-12.9%] vs 0%) and unplanned CV hospitalization (20.0% [95% CI, 15.7%-25.3%] vs 4.3% [95% CI, 1.6%-11.3%]). Over a median follow-up of 37 months (IQR, 20-64 months), the all-cause death rate was similar between patients with grade 1 vs 2 and 3 uptake; however, those with grade 2 or 3 compared with grade 1 uptake had a significantly higher risk of CV mortality (unadjusted hazard ratio, 5.30; 95% CI, 1.92-14.65).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This study shows that asymptomatic ATTR cardiac amyloid infiltration encompasses a wide spectrum of disease severity, with patients with grade 2 or 3 cardiac uptake experiencing an increased rate of CV events and CV mortality and patients with grade 1 uptake experiencing a lower CV event rate and predominantly non-CV mortality. These findings support the use of disease-modifying treatments in asymptomatic patients with grade 2 or 3 uptake and highlight the need of large-scale studies to assess their role in grade 1 uptake.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39841451/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39841451</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5221>10.1001/jamacardio.2024.5221</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39841451</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Yousuf Razvi</dc:creator>
<dc:creator>Francesco Cappelli</dc:creator>
<dc:creator>Christian Nitsche</dc:creator>
<dc:creator>Matteo Serenelli</dc:creator>
<dc:creator>Simone Longhi</dc:creator>
<dc:creator>Giulio Sinigiani</dc:creator>
<dc:creator>Alberto Cipriani</dc:creator>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Daniela Tomasoni</dc:creator>
<dc:creator>Mattia Zampieri</dc:creator>
<dc:creator>Anna Cantone</dc:creator>
<dc:creator>Valentina Allegro</dc:creator>
<dc:creator>Giuseppe Vergaro</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Marcus Urey</dc:creator>
<dc:creator>Adam Ioannou</dc:creator>
<dc:creator>Aviva Petrie</dc:creator>
<dc:creator>Navid Noory</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Michael Poledniczek</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Ana Martinez-Naharro</dc:creator>
<dc:creator>Ashutosh D Wechalekar</dc:creator>
<dc:creator>Helen Lachman</dc:creator>
<dc:creator>Carol Whelan</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration</dc:title>
<dc:identifier>pmid:39841451</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5221</dc:identifier>
</item>
<item>
<title>Yellowish Nodules on a Man Consuming a Carnivore Diet</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39841435/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 22. doi: 10.1001/jamacardio.2024.5209. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39841435/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39841435</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5209>10.1001/jamacardio.2024.5209</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39841435</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Konstantinos Marmagkiolis</dc:creator>
<dc:creator>Jaime Caballero</dc:creator>
<dc:creator>Cezar Iliescu</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Yellowish Nodules on a Man Consuming a Carnivore Diet</dc:title>
<dc:identifier>pmid:39841435</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5209</dc:identifier>
</item>
<item>
<title>Gut Microbiota Metabolites Sensed by Host GPR41/43 Protect Against Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39840468/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250123072024&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings highlight that lack of short-chain fatty acid-receptor signaling via both GPR41 and GPR43 increases risk of high blood pressure, suggesting treatments that target these receptors could be a novel strategy to prevent or treat hypertension.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 22. doi: 10.1161/CIRCRESAHA.124.325770. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Fermentation of dietary fiber by the gut microbiota leads to the production of metabolites called short-chain fatty acids, which lower blood pressure and exert cardioprotective effects. Short-chain fatty acids activate host signaling responses via the functionally redundant receptors GPR41 and GPR43, which are highly expressed by immune cells. Whether and how these receptors protect against hypertension or mediate the cardioprotective effects of dietary fiber remains unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Cardiovascular phenotype was assessed in untreated and Ang II (angiotensin II) treated hypertensive wild-type and GPR41/43 knockout (KO) double knockout male mice fed diets with different levels of fiber content. Some mice received TLR4-antagonist treatment and bone marrow chimeras. Single-nucleotide polymorphisms associated with <i>GPR41</i> and <i>GPR43</i> expression were assessed in UK Biobank participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Untreated GPR41/43KO mice had unaltered blood pressure but had greater cardiac and renal collagen deposition with higher macrophage numbers in the kidney compared with wild-type mice. Ang II-treated GPR41/43KO mice showed higher systolic blood pressure, cardiorenal weights and collagen deposition, and increased gut permeability, which allows the translocation of gastrointestinal bacterial components such as lipopolysaccharides into the circulation. The use of an antagonist to the lipopolysaccharide receptor, TLR4, a potent proinflammatory signaling molecule, restored the cardiovascular phenotype in GPR41/43KO mice. The lack of GPR41/43 expression in the immune compartment was sufficient to lead to a worsened hypertensive phenotype. We also demonstrate that GPR41/43 is, at least partially, responsible for the blood pressure-lowering and cardioprotective effects of a high-fiber diet. Finally, using the UK Biobank, we provide translational evidence that variants associated with lower expression of both GPR41 and GPR43 are more prevalent in participants with hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings highlight that lack of short-chain fatty acid-receptor signaling via both GPR41 and GPR43 increases risk of high blood pressure, suggesting treatments that target these receptors could be a novel strategy to prevent or treat hypertension.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39840468/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250123072024&v=2.18.0.post9+e462414">39840468</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325770>10.1161/CIRCRESAHA.124.325770</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39840468</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Rikeish R Muralitharan</dc:creator>
<dc:creator>Tenghao Zheng</dc:creator>
<dc:creator>Evany Dinakis</dc:creator>
<dc:creator>Liang Xie</dc:creator>
<dc:creator>Anastasia Barbaro-Wahl</dc:creator>
<dc:creator>Hamdi A Jama</dc:creator>
<dc:creator>Michael Nakai</dc:creator>
<dc:creator>Madeleine Patterson</dc:creator>
<dc:creator>Kwan Charmaine Leung</dc:creator>
<dc:creator>Zoe McArdle</dc:creator>
<dc:creator>Katrina Mirabito Colafella</dc:creator>
<dc:creator>Chad Johnson</dc:creator>
<dc:creator>Wendy Qin</dc:creator>
<dc:creator>Ekaterina Salimova</dc:creator>
<dc:creator>Natalie Bitto</dc:creator>
<dc:creator>Maria-Kaparakis Liaskos</dc:creator>
<dc:creator>David M Kaye</dc:creator>
<dc:creator>Joanne A O'Donnell</dc:creator>
<dc:creator>Charles R Mackay</dc:creator>
<dc:creator>Francine Z Marques</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Gut Microbiota Metabolites Sensed by Host GPR41/43 Protect Against Hypertension</dc:title>
<dc:identifier>pmid:39840468</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325770</dc:identifier>
</item>





























</channel>
</rss>